Two of a Kind Workin' on RPT

Donghoon Lee, CEO of SK Biopharmaceuticals, left, and Lee Jin Kyung, president of Korea Institute of Radiological and Medical Sciences (KIRAMS), pose for a photo after signing a memorandum of understanding at KIRAMS headquarters in Seoul, Sept. 4. The two sides will collaborate in radiopharmaceutical therapy (RPT), aiming to develop new anticancer drugs and manufacture therapeutic radioisotope actinium-225 in line with SK Biopharmaceuticals’ strategy to become a “global player” targeting the U.S. and Asia.  [SK Biopharmaceuticals]

Media Contact:

SK Biopharmaceuticals
Hyongki Park (H. Park)
skbp_comm@sk.com